Reversal of multidrug resistance by surfactants
…, AB Kriegler, V Nink, LK Webster… - British Journal of …, 1992 - nature.com
Cremophor EL, a pharmacologically inactive solubilising agent, has been shown to reverse
multidrug resistance (MDR). Using flow cytometric evaluation of equilibrium intracellular …
multidrug resistance (MDR). Using flow cytometric evaluation of equilibrium intracellular …
Modifying the properties of platinum (IV) complexes in order to increase biological effectiveness
…, GD Fallon, BM Gatehouse, LK Webster… - Journal of inorganic …, 1999 - Elsevier
The preparation of a series of novel Pt(IV) complexes containing the anionic polyfluoroaryl
ligands, 2,3,5,6-tetrafluorophenyl (p-HC 6 F 4 ), 2,3,5,6-tetrafluoro-4-methoxyphenyl (p-MeOC …
ligands, 2,3,5,6-tetrafluorophenyl (p-HC 6 F 4 ), 2,3,5,6-tetrafluoro-4-methoxyphenyl (p-MeOC …
Preclinical analysis of the analinoquinazoline AG1478, a specific small molecule inhibitor of EGF receptor tyrosine kinase
…, AM Scott, A Levitzki, G McLachlan, LK Webster… - Biochemical …, 2006 - Elsevier
The tyrphostin 4-(3-chloroanilino)-6,7-dimethoxyquinazoline (AG1478) is a potent and
specific inhibitor of EGFR tyrosine kinase whose favourable preclinical profile supports …
specific inhibitor of EGFR tyrosine kinase whose favourable preclinical profile supports …
Inhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80
AG Ellis, NA Crinis, LK Webster - Cancer chemotherapy and …, 1996 - Springer
Cremophor EL, a surfactant used in the clinical formulation of cyclosporine and paclitaxel,
will reverse the multidrug resistance (MDR) phenotype in vitro. As other MDR modulators can …
will reverse the multidrug resistance (MDR) phenotype in vitro. As other MDR modulators can …
Synthesis and antiproliferative activity of a series of new platinum and palladium diphosphane complexes
…, G Meyer, S Schmitz, I Ott, J Schur, LK Webster… - Dalton …, 2018 - pubs.rsc.org
… Carleen Cullinane and Lorraine Webster carried out parts of the antiproliferative tests in
Australia. These experiments were repeated and enlarged in Germany by Ingo Ott and Julia …
Australia. These experiments were repeated and enlarged in Germany by Ingo Ott and Julia …
Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer.
…, J Zalcberg, JF Bishop, LK Webster… - Journal of clinical …, 1997 - ascopubs.org
PURPOSE To determine the maximum-tolerated doses (MTDs), principal toxicities, and
pharmacokinetics of the combination of docetaxel and cisplatin administered every 3 weeks to …
pharmacokinetics of the combination of docetaxel and cisplatin administered every 3 weeks to …
cis-Bis (pyridine) platinum (II) organoamides with unexpected growth inhibition properties and antitumor activity
LK Webster, GB Deacon, DP Buxton… - Journal of medicinal …, 1992 - ACS Publications
Method B. Saponification of Peptide Esters in Aqueous Dioxane. To a solution of peptide
esters (10 mmol) in a mixture of dioxane (90 mL) and water (10 mL) was added 1 M NaOH (13 …
esters (10 mmol) in a mixture of dioxane (90 mL) and water (10 mL) was added 1 M NaOH (13 …
Phenyltin diethyldithiocarbamates: solid state and solution structures and in vitro anti-tumour activity
…, ERT Tiekink, L Gorkom, LK Webster - Main Group Metal …, 1994 - degruyter.com
Solution and cross-polarized magic-angle spinning (CP-MAS) solid state NMR data (1 3 C
and 119 Sn) for a series of phenyltin diethyldithiocarbamate compounds and the crystal …
and 119 Sn) for a series of phenyltin diethyldithiocarbamate compounds and the crystal …
Optimal sampling strategies for bayesian estimation of docetaxel (Taxotere) clearance.
P Baille, R Bruno, JH Schellens, LK Webster… - Clinical cancer research …, 1997 - AACR
Docetaxel activity has been documented in many solid tumors, including metastatic breast
cancer and non-small cell lung cancer. However, as clinical studies in other tumor types are …
cancer and non-small cell lung cancer. However, as clinical studies in other tumor types are …
Carboplatin dosing based on measurement of renal function—experience at the Peter MacCallum Cancer Institute
MJ Millward, LK Webster, GC Toner… - Australian and New …, 1996 - Wiley Online Library
Background: Carboplatin is used in treating many types of cancer. Because renal excretion
is the major variable determining the pharmacokinetics of this drug, a dosing formula based …
is the major variable determining the pharmacokinetics of this drug, a dosing formula based …